Demographics, Clinical Presentation and Outcome of GIST Patients Treated with Imatinib at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: An Eleven -year Retrospective Study
No Thumbnail Available
Date
2021-12
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Addis Abeba University
Abstract
Background: Gastrointestinal stromal tumor (GIST) is a mesenchyme tumor located primarily
in the stomach and small intestine, but can occur in any portion of the alimentary tract including
occasionally in the omentum, mesentery, and peritoneum. Up to 80 % of GISTs result from gainof-function
mutations
in
the
KIT
gene,
and
approximately
85–95
%
of
GISTs
stain
positive
for
the
KIT
protein
(CD117).
There
i
slight
increases
prevalence
in
males.
The
median
age
is
around
60–65
years
in
western
population.
The
use
of
imatinib
to
selectively
inhibit
KIT
and
PDGFRA
receptor
tyrosine
kinases
is
highly
effective
in
the
treatment
of
metastatic
GIST
and
as
adjuvant
treatment.
Objective :The main objective of this to study to characterize ,Demographics, Clinical
Presentation and Outcome of GIST Patients Treated with Imatinib at Tikur Anbessa Specialized
Hospital, Addis Ababa, Ethiopia.
Method: A retrospective cross sectional design, patients with GIST enrolled in the Glivec
International Patient Assistance Program (GIPAP) from January 1 2004 to August 30, 2021. All
adult patients diagnosed with advanced GIST and adjunctive imatinib treatments were included
and treatment response assessed using response evaluation criteria in solid tumors (RECIST).
Results: There are more than hundred GIST patients on imatinib at hematology clinic at TASH.
Fifty eight patients with pathologically confirmed GIST, with abdominal CT scan taking
imatinib were enrolled. The median age is 52 (ranges 20-83). 27.6% of were less than 45 age.
Thirty two (55%) of GIST patients were male and twenty six (45%) were females with slight
male predominance. Thirty seven (64%) had tumor originated from stomach and, twenty two
patients had metastatic stage 4 disease. Metastasis to liver was the commonest site occurred in
nine (15.5%). Surgical resection was the most frequent treatment; done for fifty (86.2%) patients.
median duration of treatment with imatinib were 2.9 years. Out of sixteen patients with
metastatic diseases, six (37.5) achieved PR, three (18.75) had SD four (25%) had PD. From a
total of forty two patients taking adjunctive imatinib treatment thirty three (78.5%) achieved CR,
and eight (19) patients was in PR.
Conclusion: This study showed Imatinib had a high efficacy both in patients with unresectable
GIST/metastatic GIST and in those given as adjuvant treatments at the TASH.However it was
more effective as adjuvant treatment.
Description
Keywords
GIST, Imatinib,